In solid tumor malignancies, CRS is less well defined and incidence of ICANS is not well reported with setback in June of 2021 for the use of CAR T in solid tumors after Tmunity Therapeutics halted its phase 1 clinical trial of prostate-specific membrane antigen (PSMA)-directed, TGF- β sensitive CAR T cells for prostate cancer after two fatalities from ICANS. This evidence concerns the gene FOLH1 and prostate carcinoma.